Literature DB >> 7587435

Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS.

G U Meduri1, S Headley, E Tolley, M Shelby, F Stentz, A Postlethwaite.   

Abstract

BACKGROUND: In late ARDS, a persistent and exaggerated inflammatory response causes recurrent injury to the alveolocapillary barrier and amplification of intra-alveolar fibroproliferation. When ARDS patients fail to improve, corticosteroid (CS) rescue treatment frequently leads to rapid improvements in lung function. We tested the hypothesis that response to CS treatment is related to suppressing the inflammatory response by comparing changes in lung function to inflammatory cytokine (IC) levels in the plasma and BAL.
METHODS: Blood samples were obtained on days 1, 3, 5, and 7 of ARDS, and on days -5, -3, 0 (initiation of treatment), +3, +5, +7, +10, and +14 of CS treatment. Bilateral BAL was obtained on day 1 of ARDS, before administration of CS treatment, and at weekly intervals. We analyzed changes in IC levels during CS treatment in relation to improvements in lung injury score (LIS), indices of endothelial permeability, and final outcome. We also analyzed data to identify timing to a significant reduction in plasma IC levels and predictors of response.
RESULTS: Nine patients entered the study. CS treatment was initiated 15 +/- 9 days into ARDS. Improvement in LIS (> 1-point reduction) was rapid (< 7 days) in five, delayed (< 14 days) in two, and absent in two. Baseline plasma and BAL IC levels in study patients were similar to a previously reported comparison group of 12 ARDS nonsurvivors. No significant changes in plasma and BAL IC levels were observed before CS administration. Following initiation of CS treatment, significant reductions in plasma tumor necrosis factor-alpha and interleukin 6 (IL-6) levels were seen by day 7 in both rapid and delayed responders (p = 0.03). IL-1 beta was significantly reduced by day 5 (p = 0.04) in rapid responders and by day 10 (p = 0.03) in delayed responders. In responders, improvement in LIS and BAL albumin paralleled reduction in plasma and BAL IC levels. At initiation of treatment, rapid responders had significantly lower tumor necrosis factor-alpha and IL-6 levels. Nonresponders had a significantly higher plasma IL-6 level on days 1 to 3 of ARDS (p = 0.004) and lower ratio of arteriolar oxygen tension to inspired oxygen concentration at initiation of treatment (p < 0.01).
CONCLUSIONS: In patients with late ARDS and a low likelihood of survival, prolonged corticosteroid rescue treatment was associated with a reduction in plasma and BAL IC levels and parallel improvements in indices of endothelial permeability and LIS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587435     DOI: 10.1378/chest.108.5.1315

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury.

Authors:  Ozlem U Gurkan; Chaoxia He; Rachel Zielinski; Hamid Rabb; Landon S King; Jeffrey M Dodd-o; Franco R D'Alessio; Neil Aggarwal; David Pearse; Patrice M Becker
Journal:  Exp Lung Res       Date:  2011-11-01       Impact factor: 2.459

Review 3.  [Corticosteroid administration for acute respiratory distress syndrome : therapeutic option?].

Authors:  P Möhnle; J Briegel
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

Review 4.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

5.  Effects of methylprednisolone on intracellular bacterial growth.

Authors:  G U Meduri; S Kanangat; M Bronze; D R Patterson; C U Meduri; C Pak; E A Tolley; D R Schaberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

6.  Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins.

Authors:  Andreas Schwingshackl; Benjamin Lopez; Bin Teng; Charlean Luellen; Florian Lesage; John Belperio; Riccardo Olcese; Christopher M Waters
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-24       Impact factor: 5.464

7.  Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls.

Authors:  T T Bauer; C Montón; A Torres; H Cabello; X Fillela; A Maldonado; J M Nicolás; E Zavala
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 8.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: Results from a double-blind, placebo-controlled randomized pilot trial.

Authors:  Andreas Schwingshackl; Dai Kimura; Cynthia R Rovnaghi; Jordy S Saravia; Stephania A Cormier; Bin Teng; Alina N West; Umberto G Meduri; Kanwaljeet J S Anand
Journal:  Cytokine       Date:  2015-11-03       Impact factor: 3.861

Review 10.  COVID-19: Lung-Centric Immunothrombosis.

Authors:  Peter R Kvietys; Hana M A Fakhoury; Sana Kadan; Ahmed Yaqinuddin; Eid Al-Mutairy; Khaled Al-Kattan
Journal:  Front Cell Infect Microbiol       Date:  2021-06-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.